| Identification | Back Directory | [Name]
BIIB028 | [CAS]
911398-13-5 | [Synonyms]
BIIB028
BMZGPNGECPQAGB-UHFFFAOYSA-N
3-Butyn-1-ol, 4-[2-amino-4-chloro-7-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, 1-(dihydrogen phosphate) | [Molecular Formula]
C19H21ClN5O5P | [MDL Number]
MFCD28902219 | [MOL File]
911398-13-5.mol | [Molecular Weight]
465.83 |
| Hazard Information | Back Directory | [Uses]
BIIB-028 is an orally active inhibitor for heat shock protein 90 (Hsp90). BIIB-028 targets the ATP-binding site of Hsp90, disrupts the function of Hsp90, leads to the degradation of client proteins, that are crucial for cancer cell survival and proliferation[1][2]. | [References]
[1] Soga S, et al., Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des. 2013;19(3):366-76. DOI:10.2174/138161213804143617
[2] Rahimi M N. Investigating cyclic peptide inhibitors of heat shock protein 90 (Hsp90): from design and synthesis to cellular drug delivery[D]. UNSW Sydney, 2020. |
|
|